SCHEMBL9957782

SCHEMBL9957782

[c]1cccc(-c2csc(-c3ccccc3)n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.62
KMT2A Q03164 4/20 0.62
AR P10275 1/20 0.62
SREBF2 Q12772 1/20 0.58
RAB9A P51151 7/20 0.57
NPC1 O15118 4/20 0.57
CYP19A1 P11511 3/20 0.57
SMN1; SMN2 Q16637 5/20 0.54
ALDH1A1 P00352 3/20 0.54
MAPT P10636 3/20 0.54
MEN1 O00255 3/20 0.54
LMNA P02545 2/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.54
PKM P14618 1/20 0.54
HPGD P15428 1/20 0.54
ALOX12 P18054 1/20 0.54
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3801938 0.93 KDM4E (0.51) KDM4EKMT2AARSREBF2RAB9A
SCHEMBL714474 0.84 KDM4E (0.69) KDM4EKMT2AARSREBF2RAB9A
SCHEMBL694619 0.84 KDM4E (0.69) KDM4EKMT2AARSREBF2RAB9A
SCHEMBL2781370 0.83 KDM4E (0.85) KDM4EKMT2AARSREBF2RAB9A
SCHEMBL11215130 0.81 SREBF2 (0.82) KDM4EKMT2AARSREBF2RAB9A
SCHEMBL11213828 0.81 SREBF2 (0.82) KDM4EKMT2AARSREBF2RAB9A
SCHEMBL11212983 0.81 SREBF2 (0.82) KDM4EKMT2AARSREBF2RAB9A
SCHEMBL6217477 0.81 ALDH1A1 (0.62) KDM4EKMT2AARRAB9ANPC1
SCHEMBL11464717 0.80 SREBF2 (0.79) KDM4EKMT2AARSREBF2RAB9A
SCHEMBL61174 0.79 RECQL (0.53) KDM4ESREBF2RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624193-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2017-04-18 US disclosed
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORPORATION (JP) 2015-11-19 US disclosed
US-9120773-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2015-09-01 US disclosed
EP-2818462-A1 Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component TOSOH CORPORATION (JP) 2014-12-31 EP disclosed
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) 2012-08-23 US disclosed
CN-102574813-A Cyclic azine derivatives, process for producing the same, and organic electroluminescent element containing the same as constituent TOSOH CORP 2012-07-11 CN disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 KDM4E 577/4885KMT2A 3592/4885AR 379/4885
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 KDM4E 577/4885KMT2A 3592/4885AR 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.